Quick Dispatch:
Your retatrutide triumph A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your retatrutide triumph A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) ships.
Need Help?
Questions about retatrutide triumph A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for retatrutide triumph A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) in your area.
TRIUMPH-1 Topline Results for Retatrutide (reh-TAH-troo-tide): Mean 28.3% total body weight loss at 80 weeks in people with obesity and without diabetes — with continued loss to 30.3% at 104 weeks in… |
28.09
🚨 HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average
29.05
Retatrutide Explained: Mechanism, Phase 3 TRIUMPH-1 Results, Safety, and Future Potential – C2 Peptides
26.13
Lilly's Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
20.51
Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1
20.89
A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks
20.05
Eli Lilly retatrutide Phase 3 obesity trial results 2026
24.50
